 Kian Behbakht
Concepts (439)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Ovarian Neoplasms | 40 | 2024 | 420 | 5.550 |
Why?
| | Poly(ADP-ribose) Polymerase Inhibitors | 6 | 2023 | 76 | 1.320 |
Why?
| | Endometrial Neoplasms | 10 | 2019 | 144 | 1.180 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 9 | 2020 | 1390 | 1.100 |
Why?
| | Drug Resistance, Neoplasm | 15 | 2023 | 671 | 1.060 |
Why?
| | Genital Neoplasms, Female | 6 | 2020 | 72 | 1.030 |
Why?
| | Uterine Cervical Neoplasms | 8 | 2017 | 216 | 1.020 |
Why?
| | Peritoneal Neoplasms | 6 | 2022 | 53 | 1.020 |
Why?
| | Hysterectomy | 4 | 2018 | 117 | 0.820 |
Why?
| | Antineoplastic Agents | 10 | 2023 | 1974 | 0.820 |
Why?
| | TNF-Related Apoptosis-Inducing Ligand | 5 | 2017 | 56 | 0.730 |
Why?
| | Biomarkers, Tumor | 8 | 2019 | 1059 | 0.700 |
Why?
| | Cystadenocarcinoma, Serous | 5 | 2022 | 49 | 0.700 |
Why?
| | Gelatin | 2 | 2016 | 35 | 0.680 |
Why?
| | Neoplasms, Glandular and Epithelial | 3 | 2015 | 41 | 0.650 |
Why?
| | Models, Economic | 1 | 2018 | 48 | 0.640 |
Why?
| | Thrombin | 2 | 2016 | 143 | 0.640 |
Why?
| | Hyperthermia, Induced | 1 | 2018 | 67 | 0.630 |
Why?
| | Pelvic Infection | 1 | 2016 | 4 | 0.570 |
Why?
| | Homeodomain Proteins | 3 | 2012 | 468 | 0.570 |
Why?
| | Tissue Adhesives | 1 | 2016 | 18 | 0.560 |
Why?
| | Female | 79 | 2024 | 61547 | 0.560 |
Why?
| | Fallopian Tube Neoplasms | 5 | 2019 | 15 | 0.540 |
Why?
| | Cost-Benefit Analysis | 1 | 2018 | 554 | 0.530 |
Why?
| | Neoplastic Cells, Circulating | 2 | 2017 | 62 | 0.530 |
Why?
| | Neoplasm Recurrence, Local | 6 | 2019 | 900 | 0.510 |
Why?
| | Cell Line, Tumor | 18 | 2023 | 2849 | 0.500 |
Why?
| | Women | 1 | 2015 | 51 | 0.500 |
Why?
| | Sirolimus | 2 | 2016 | 195 | 0.490 |
Why?
| | Vagina | 5 | 2016 | 148 | 0.430 |
Why?
| | Health Knowledge, Attitudes, Practice | 2 | 2015 | 1184 | 0.430 |
Why?
| | Antibodies, Neoplasm | 1 | 2012 | 30 | 0.420 |
Why?
| | Middle Aged | 46 | 2020 | 27607 | 0.420 |
Why?
| | Cisplatin | 2 | 2015 | 271 | 0.420 |
Why?
| | Humans | 83 | 2024 | 118931 | 0.390 |
Why?
| | Claudin-4 | 3 | 2022 | 9 | 0.370 |
Why?
| | Neoadjuvant Therapy | 4 | 2020 | 333 | 0.370 |
Why?
| | Neoplasm Staging | 14 | 2019 | 1221 | 0.370 |
Why?
| | Aged | 34 | 2020 | 19644 | 0.360 |
Why?
| | Uterine Neoplasms | 4 | 2019 | 76 | 0.360 |
Why?
| | Robotic Surgical Procedures | 3 | 2016 | 89 | 0.360 |
Why?
| | Pelvic Exenteration | 1 | 2009 | 12 | 0.360 |
Why?
| | Leiomyosarcoma | 3 | 2020 | 23 | 0.350 |
Why?
| | Cytoreduction Surgical Procedures | 2 | 2020 | 40 | 0.350 |
Why?
| | Paclitaxel | 3 | 2019 | 195 | 0.350 |
Why?
| | Pyrimidines | 3 | 2019 | 382 | 0.350 |
Why?
| | Health Personnel | 1 | 2015 | 586 | 0.350 |
Why?
| | Aged, 80 and over | 17 | 2020 | 6555 | 0.350 |
Why?
| | Phthalazines | 2 | 2019 | 47 | 0.340 |
Why?
| | Receptors, TNF-Related Apoptosis-Inducing Ligand | 3 | 2017 | 34 | 0.340 |
Why?
| | Apoptosis | 8 | 2019 | 2484 | 0.340 |
Why?
| | Carcinoma, Endometrioid | 3 | 2019 | 47 | 0.330 |
Why?
| | Chemotherapy, Adjuvant | 2 | 2020 | 360 | 0.320 |
Why?
| | Carbazoles | 1 | 2008 | 80 | 0.320 |
Why?
| | Azepines | 2 | 2019 | 74 | 0.320 |
Why?
| | Caffeine | 1 | 2008 | 61 | 0.320 |
Why?
| | Clinical Competence | 1 | 2015 | 951 | 0.320 |
Why?
| | Postoperative Complications | 6 | 2020 | 2235 | 0.310 |
Why?
| | Papanicolaou Test | 2 | 2004 | 40 | 0.300 |
Why?
| | Vaginal Smears | 2 | 2004 | 49 | 0.300 |
Why?
| | Piperazines | 2 | 2019 | 316 | 0.300 |
Why?
| | Adult | 29 | 2020 | 31508 | 0.290 |
Why?
| | Protein Kinase C | 1 | 2008 | 297 | 0.290 |
Why?
| | Hemostasis, Surgical | 2 | 2016 | 22 | 0.270 |
Why?
| | Adenocarcinoma | 4 | 2015 | 811 | 0.260 |
Why?
| | Laparotomy | 2 | 2015 | 106 | 0.260 |
Why?
| | Urban Health | 1 | 2004 | 78 | 0.250 |
Why?
| | Disease-Free Survival | 7 | 2017 | 648 | 0.250 |
Why?
| | Gene Expression Regulation, Neoplastic | 6 | 2020 | 1167 | 0.240 |
Why?
| | Fallopian Tubes | 1 | 2024 | 28 | 0.240 |
Why?
| | Pyrazoles | 2 | 2020 | 363 | 0.230 |
Why?
| | Genetic Therapy | 2 | 2014 | 267 | 0.230 |
Why?
| | Uterine Cervical Dysplasia | 2 | 2003 | 38 | 0.220 |
Why?
| | Adenocarcinoma, Clear Cell | 2 | 2021 | 14 | 0.210 |
Why?
| | Leiomyoma | 2 | 2019 | 45 | 0.210 |
Why?
| | Healthcare Disparities | 2 | 2018 | 495 | 0.210 |
Why?
| | Prognosis | 8 | 2020 | 3440 | 0.200 |
Why?
| | Hospitals, Public | 1 | 2001 | 24 | 0.200 |
Why?
| | Piperidines | 2 | 2019 | 171 | 0.200 |
Why?
| | BRCA2 Protein | 3 | 2019 | 44 | 0.190 |
Why?
| | Treatment Outcome | 11 | 2020 | 9341 | 0.190 |
Why?
| | Vulvar Neoplasms | 1 | 2020 | 10 | 0.190 |
Why?
| | Hospitals, University | 1 | 2001 | 172 | 0.190 |
Why?
| | Cervix Uteri | 3 | 2011 | 48 | 0.190 |
Why?
| | Mutation | 5 | 2019 | 3457 | 0.190 |
Why?
| | Epoxy Compounds | 1 | 2020 | 33 | 0.180 |
Why?
| | Neoplasms | 4 | 2017 | 2177 | 0.180 |
Why?
| | Enoxaparin | 1 | 2020 | 51 | 0.180 |
Why?
| | Carnitine O-Palmitoyltransferase | 1 | 2020 | 47 | 0.180 |
Why?
| | Rad51 Recombinase | 1 | 2019 | 13 | 0.180 |
Why?
| | Cell Movement | 2 | 2016 | 896 | 0.180 |
Why?
| | Receptors, Adiponectin | 1 | 2019 | 14 | 0.180 |
Why?
| | Vaccines, Conjugate | 1 | 2019 | 63 | 0.180 |
Why?
| | Pyridones | 1 | 2020 | 119 | 0.170 |
Why?
| | Up-Regulation | 2 | 2020 | 872 | 0.170 |
Why?
| | Histocompatibility Antigens | 1 | 2019 | 102 | 0.170 |
Why?
| | Poly(ADP-ribose) Polymerases | 1 | 2019 | 87 | 0.170 |
Why?
| | Patient Acceptance of Health Care | 1 | 2004 | 686 | 0.170 |
Why?
| | Interleukin-12 | 2 | 2014 | 110 | 0.170 |
Why?
| | Sequence Analysis, RNA | 2 | 2019 | 409 | 0.170 |
Why?
| | Sarcoma | 1 | 2020 | 137 | 0.170 |
Why?
| | Histone-Lysine N-Methyltransferase | 1 | 2019 | 99 | 0.160 |
Why?
| | Cancer Vaccines | 1 | 2019 | 139 | 0.160 |
Why?
| | Lymph Node Excision | 2 | 2020 | 158 | 0.160 |
Why?
| | Ovariectomy | 2 | 2015 | 124 | 0.160 |
Why?
| | Adjuvants, Immunologic | 1 | 2019 | 207 | 0.160 |
Why?
| | Oncologists | 1 | 2018 | 31 | 0.160 |
Why?
| | Cost Savings | 1 | 2018 | 77 | 0.160 |
Why?
| | Breast Neoplasms | 4 | 2019 | 1964 | 0.160 |
Why?
| | Cell Growth Processes | 2 | 2008 | 54 | 0.160 |
Why?
| | Pregnancy Complications, Infectious | 1 | 2002 | 296 | 0.160 |
Why?
| | Aurora Kinase A | 1 | 2017 | 52 | 0.150 |
Why?
| | Neoplasm Grading | 4 | 2019 | 258 | 0.150 |
Why?
| | Dose-Response Relationship, Drug | 4 | 2008 | 1944 | 0.150 |
Why?
| | Antineoplastic Agents, Phytogenic | 1 | 2019 | 180 | 0.150 |
Why?
| | Tumor Microenvironment | 1 | 2020 | 454 | 0.150 |
Why?
| | Leukocyte Common Antigens | 1 | 2017 | 76 | 0.150 |
Why?
| | Survival Rate | 5 | 2020 | 1720 | 0.150 |
Why?
| | beta Catenin | 1 | 2019 | 219 | 0.150 |
Why?
| | Anion Transport Proteins | 1 | 2017 | 12 | 0.150 |
Why?
| | Fatty Acids | 1 | 2020 | 407 | 0.150 |
Why?
| | Salpingectomy | 2 | 2015 | 13 | 0.150 |
Why?
| | Sexual Dysfunctions, Psychological | 1 | 2017 | 31 | 0.150 |
Why?
| | Gestational Trophoblastic Disease | 1 | 2016 | 6 | 0.150 |
Why?
| | Curettage | 1 | 2016 | 9 | 0.150 |
Why?
| | Keratins | 1 | 2017 | 174 | 0.150 |
Why?
| | Venous Thromboembolism | 1 | 2020 | 234 | 0.140 |
Why?
| | Risk Factors | 6 | 2016 | 8998 | 0.140 |
Why?
| | Minority Groups | 1 | 2018 | 237 | 0.140 |
Why?
| | Megestrol Acetate | 1 | 2016 | 2 | 0.140 |
Why?
| | Carcinoma, Neuroendocrine | 1 | 2016 | 31 | 0.140 |
Why?
| | Sexual Dysfunction, Physiological | 1 | 2017 | 60 | 0.140 |
Why?
| | Neoplasms, Squamous Cell | 1 | 1996 | 6 | 0.140 |
Why?
| | Colony Count, Microbial | 1 | 2016 | 120 | 0.140 |
Why?
| | Standard of Care | 1 | 2016 | 63 | 0.140 |
Why?
| | Medroxyprogesterone Acetate | 1 | 2015 | 30 | 0.140 |
Why?
| | Adenoviridae | 1 | 1996 | 191 | 0.140 |
Why?
| | Brachytherapy | 1 | 2016 | 103 | 0.140 |
Why?
| | Anticoagulants | 1 | 2020 | 559 | 0.140 |
Why?
| | Gene Expression Profiling | 2 | 2019 | 1597 | 0.140 |
Why?
| | Molecular Targeted Therapy | 1 | 2018 | 356 | 0.130 |
Why?
| | Gynecology | 1 | 2018 | 184 | 0.130 |
Why?
| | Keratin-5 | 1 | 2015 | 47 | 0.130 |
Why?
| | Animals | 12 | 2020 | 33381 | 0.130 |
Why?
| | Tretinoin | 1 | 1996 | 116 | 0.130 |
Why?
| | Chemoradiotherapy | 1 | 2016 | 199 | 0.130 |
Why?
| | Tamoxifen | 1 | 2016 | 198 | 0.130 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2017 | 982 | 0.130 |
Why?
| | Immunohistochemistry | 3 | 2016 | 1691 | 0.130 |
Why?
| | Antineoplastic Agents, Hormonal | 1 | 2015 | 143 | 0.130 |
Why?
| | Combined Modality Therapy | 4 | 2020 | 1166 | 0.130 |
Why?
| | CA-125 Antigen | 2 | 2008 | 14 | 0.130 |
Why?
| | Abdominal Abscess | 1 | 2014 | 27 | 0.120 |
Why?
| | Surgeons | 1 | 2018 | 243 | 0.120 |
Why?
| | Immunotherapy | 1 | 2018 | 493 | 0.120 |
Why?
| | Mice, SCID | 2 | 2012 | 333 | 0.120 |
Why?
| | Reoperation | 1 | 2016 | 557 | 0.120 |
Why?
| | Young Adult | 5 | 2020 | 10793 | 0.120 |
Why?
| | Lipid Metabolism | 1 | 2017 | 477 | 0.120 |
Why?
| | Glycoproteins | 1 | 2015 | 319 | 0.120 |
Why?
| | Kaplan-Meier Estimate | 4 | 2020 | 841 | 0.120 |
Why?
| | Endometrium | 1 | 2014 | 61 | 0.120 |
Why?
| | Cytokines | 1 | 2002 | 1900 | 0.120 |
Why?
| | Interpersonal Relations | 1 | 2017 | 345 | 0.120 |
Why?
| | Quality of Health Care | 1 | 2018 | 586 | 0.120 |
Why?
| | Proto-Oncogene Proteins c-akt | 2 | 2016 | 420 | 0.110 |
Why?
| | Transforming Growth Factor beta | 1 | 1996 | 462 | 0.110 |
Why?
| | Pelvic Neoplasms | 1 | 2013 | 20 | 0.110 |
Why?
| | Antigens, CD | 1 | 2015 | 460 | 0.110 |
Why?
| | Genes, Tumor Suppressor | 3 | 1998 | 77 | 0.110 |
Why?
| | Plasmids | 1 | 2014 | 355 | 0.110 |
Why?
| | Models, Biological | 3 | 2019 | 1715 | 0.110 |
Why?
| | Mice | 8 | 2020 | 15520 | 0.110 |
Why?
| | Neoplastic Stem Cells | 1 | 2015 | 336 | 0.110 |
Why?
| | RNA, Messenger | 2 | 2012 | 2656 | 0.100 |
Why?
| | Escherichia coli | 1 | 2016 | 758 | 0.100 |
Why?
| | Antibody Specificity | 1 | 2012 | 184 | 0.100 |
Why?
| | Endocrine Gland Neoplasms | 1 | 2011 | 1 | 0.100 |
Why?
| | Transplantation, Heterologous | 1 | 2012 | 194 | 0.100 |
Why?
| | Cell Division | 2 | 2008 | 776 | 0.100 |
Why?
| | RNA, Small Interfering | 3 | 2020 | 564 | 0.100 |
Why?
| | Cyclin D1 | 1 | 2011 | 61 | 0.100 |
Why?
| | Drug Synergism | 2 | 2011 | 339 | 0.100 |
Why?
| | Proteasome Inhibitors | 1 | 2011 | 44 | 0.100 |
Why?
| | MicroRNAs | 1 | 2017 | 637 | 0.100 |
Why?
| | Adenocarcinoma, Mucinous | 1 | 2011 | 59 | 0.100 |
Why?
| | Cadherins | 1 | 2011 | 186 | 0.090 |
Why?
| | Transfection | 2 | 2007 | 888 | 0.090 |
Why?
| | Peptides | 1 | 2015 | 879 | 0.090 |
Why?
| | DNA | 1 | 2017 | 1388 | 0.090 |
Why?
| | Cell Proliferation | 4 | 2019 | 2275 | 0.090 |
Why?
| | Neoplasm Invasiveness | 3 | 2016 | 462 | 0.090 |
Why?
| | Lymphoma | 1 | 2011 | 180 | 0.090 |
Why?
| | Inflammation | 1 | 2020 | 2566 | 0.090 |
Why?
| | Age Factors | 5 | 2016 | 2995 | 0.090 |
Why?
| | Adolescent | 5 | 2020 | 18480 | 0.090 |
Why?
| | Skin Transplantation | 1 | 2009 | 58 | 0.090 |
Why?
| | Anastomosis, Surgical | 1 | 2009 | 146 | 0.090 |
Why?
| | Cell Survival | 3 | 2017 | 1047 | 0.080 |
Why?
| | Papillomaviridae | 2 | 2002 | 101 | 0.080 |
Why?
| | Urokinase-Type Plasminogen Activator | 1 | 2008 | 30 | 0.080 |
Why?
| | Adaptor Proteins, Signal Transducing | 1 | 2011 | 394 | 0.080 |
Why?
| | G2 Phase | 1 | 2008 | 33 | 0.080 |
Why?
| | TOR Serine-Threonine Kinases | 1 | 2011 | 368 | 0.080 |
Why?
| | Rectum | 1 | 2009 | 157 | 0.080 |
Why?
| | Radiation-Protective Agents | 1 | 2008 | 27 | 0.080 |
Why?
| | Case-Control Studies | 4 | 2019 | 3171 | 0.080 |
Why?
| | Genes, BRCA1 | 2 | 1998 | 31 | 0.080 |
Why?
| | Models, Statistical | 1 | 2011 | 636 | 0.080 |
Why?
| | Heterografts | 2 | 2019 | 130 | 0.080 |
Why?
| | Microsatellite Instability | 2 | 2019 | 31 | 0.080 |
Why?
| | Class I Phosphatidylinositol 3-Kinases | 2 | 2019 | 80 | 0.080 |
Why?
| | Urinary Bladder | 1 | 2009 | 180 | 0.080 |
Why?
| | Xenograft Model Antitumor Assays | 2 | 2020 | 740 | 0.080 |
Why?
| | Cell Culture Techniques | 2 | 2020 | 356 | 0.070 |
Why?
| | Cysteine | 1 | 2008 | 184 | 0.070 |
Why?
| | Tumor Suppressor Protein p53 | 3 | 2019 | 455 | 0.070 |
Why?
| | Retrospective Studies | 6 | 2020 | 12972 | 0.070 |
Why?
| | Gynecologic Surgical Procedures | 2 | 2020 | 49 | 0.070 |
Why?
| | PTEN Phosphohydrolase | 2 | 2019 | 143 | 0.070 |
Why?
| | Double-Blind Method | 3 | 2019 | 1687 | 0.070 |
Why?
| | Length of Stay | 3 | 2015 | 1032 | 0.070 |
Why?
| | Adenosarcoma | 2 | 2005 | 3 | 0.070 |
Why?
| | Follow-Up Studies | 4 | 2020 | 4596 | 0.070 |
Why?
| | Proportional Hazards Models | 3 | 2020 | 1125 | 0.070 |
Why?
| | Models, Animal | 1 | 2008 | 363 | 0.070 |
Why?
| | Signal Transduction | 4 | 2012 | 4709 | 0.070 |
Why?
| | Indazoles | 2 | 2019 | 60 | 0.070 |
Why?
| | United States | 5 | 2022 | 12541 | 0.070 |
Why?
| | Intestinal Neoplasms | 1 | 2005 | 23 | 0.070 |
Why?
| | Colposcopy | 2 | 2003 | 17 | 0.070 |
Why?
| | Ovary | 1 | 2007 | 205 | 0.070 |
Why?
| | Cell Cycle | 1 | 2008 | 550 | 0.070 |
Why?
| | Cell Count | 2 | 2015 | 315 | 0.070 |
Why?
| | Germ-Line Mutation | 2 | 1996 | 134 | 0.070 |
Why?
| | Sexual Behavior | 1 | 2009 | 437 | 0.070 |
Why?
| | Neoplasm Proteins | 3 | 1998 | 400 | 0.070 |
Why?
| | Disease Progression | 3 | 2019 | 2490 | 0.060 |
Why?
| | Ultraviolet Rays | 1 | 2008 | 381 | 0.060 |
Why?
| | Chicago | 1 | 2004 | 45 | 0.060 |
Why?
| | Tumor Cells, Cultured | 2 | 1996 | 874 | 0.060 |
Why?
| | Blood Loss, Surgical | 2 | 2015 | 87 | 0.060 |
Why?
| | Transcription Factors | 4 | 2011 | 1570 | 0.060 |
Why?
| | Peptide Fragments | 1 | 2008 | 702 | 0.060 |
Why?
| | Antioxidants | 1 | 2008 | 564 | 0.060 |
Why?
| | Survival Analysis | 4 | 2020 | 1266 | 0.060 |
Why?
| | Polymerase Chain Reaction | 3 | 2002 | 1012 | 0.060 |
Why?
| | Activating Transcription Factor 6 | 1 | 2023 | 18 | 0.060 |
Why?
| | Receptors, Estrogen | 2 | 2015 | 387 | 0.060 |
Why?
| | Transcription Factor AP-1 | 1 | 2023 | 81 | 0.050 |
Why?
| | Neoplasm Metastasis | 2 | 2015 | 544 | 0.050 |
Why?
| | Women's Health | 1 | 2004 | 273 | 0.050 |
Why?
| | X-ray Repair Cross Complementing Protein 1 | 1 | 2022 | 16 | 0.050 |
Why?
| | Gardnerella vaginalis | 1 | 2002 | 2 | 0.050 |
Why?
| | Trichomonas vaginalis | 1 | 2002 | 9 | 0.050 |
Why?
| | Vaginal Neoplasms | 1 | 2001 | 11 | 0.050 |
Why?
| | Phosphatidylinositol 3-Kinases | 2 | 2016 | 341 | 0.050 |
Why?
| | Risk Assessment | 3 | 2016 | 3055 | 0.050 |
Why?
| | Yeasts | 1 | 2002 | 52 | 0.050 |
Why?
| | Vaginal Diseases | 1 | 2001 | 17 | 0.050 |
Why?
| | Pregnancy | 3 | 2016 | 5690 | 0.050 |
Why?
| | Gene Expression | 1 | 2007 | 1488 | 0.050 |
Why?
| | Endometriosis | 1 | 2001 | 42 | 0.050 |
Why?
| | Epithelial Cells | 1 | 2007 | 963 | 0.050 |
Why?
| | Databases, Factual | 2 | 2016 | 1231 | 0.050 |
Why?
| | DNA, Neoplasm | 2 | 1998 | 154 | 0.050 |
Why?
| | Vulvectomy | 1 | 2020 | 2 | 0.050 |
Why?
| | Histiocytoma, Malignant Fibrous | 1 | 2020 | 4 | 0.050 |
Why?
| | Dermatofibrosarcoma | 1 | 2020 | 9 | 0.050 |
Why?
| | DNA Primers | 1 | 2002 | 533 | 0.050 |
Why?
| | Hospitals, Urban | 1 | 2001 | 129 | 0.050 |
Why?
| | Clinical Trials, Phase I as Topic | 1 | 2020 | 47 | 0.050 |
Why?
| | Alleles | 3 | 2017 | 832 | 0.050 |
Why?
| | DNA Repair | 1 | 2022 | 198 | 0.050 |
Why?
| | Prospective Studies | 4 | 2016 | 6471 | 0.050 |
Why?
| | Liposarcoma | 1 | 2020 | 26 | 0.050 |
Why?
| | Medically Uninsured | 1 | 2001 | 125 | 0.050 |
Why?
| | Anoikis | 1 | 2020 | 35 | 0.050 |
Why?
| | Hemocyanins | 1 | 2019 | 57 | 0.050 |
Why?
| | Interleukin-10 | 1 | 2002 | 306 | 0.040 |
Why?
| | Rhabdomyosarcoma | 1 | 2020 | 57 | 0.040 |
Why?
| | Chitinase-3-Like Protein 1 | 1 | 2019 | 17 | 0.040 |
Why?
| | Diagnosis, Differential | 2 | 2019 | 1384 | 0.040 |
Why?
| | DNA Damage | 1 | 2022 | 357 | 0.040 |
Why?
| | SEER Program | 1 | 2020 | 205 | 0.040 |
Why?
| | Logistic Models | 1 | 2004 | 1900 | 0.040 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2002 | 827 | 0.040 |
Why?
| | Neoplasms, Cystic, Mucinous, and Serous | 1 | 2019 | 24 | 0.040 |
Why?
| | Poly-ADP-Ribose Binding Proteins | 1 | 2019 | 23 | 0.040 |
Why?
| | Lymphatic Metastasis | 1 | 2020 | 307 | 0.040 |
Why?
| | Intramolecular Oxidoreductases | 1 | 2019 | 59 | 0.040 |
Why?
| | DNA Polymerase II | 1 | 2019 | 29 | 0.040 |
Why?
| | Radiotherapy | 1 | 2020 | 187 | 0.040 |
Why?
| | Cell Cycle Checkpoints | 1 | 2019 | 87 | 0.040 |
Why?
| | Chromosomes, Human, Pair 7 | 1 | 1998 | 15 | 0.040 |
Why?
| | Gene Knockdown Techniques | 1 | 2020 | 311 | 0.040 |
Why?
| | Mechanistic Target of Rapamycin Complex 1 | 1 | 2019 | 104 | 0.040 |
Why?
| | Cytoskeletal Proteins | 1 | 2019 | 146 | 0.040 |
Why?
| | Mitosis | 1 | 2019 | 172 | 0.040 |
Why?
| | AMP-Activated Protein Kinases | 1 | 2019 | 178 | 0.040 |
Why?
| | Microtubule-Associated Proteins | 1 | 2019 | 187 | 0.040 |
Why?
| | Europe | 1 | 2019 | 356 | 0.040 |
Why?
| | Interleukin-6 | 1 | 2002 | 688 | 0.040 |
Why?
| | Colorectal Neoplasms, Hereditary Nonpolyposis | 1 | 1998 | 31 | 0.040 |
Why?
| | Image Cytometry | 1 | 2017 | 3 | 0.040 |
Why?
| | Wnt Signaling Pathway | 1 | 2019 | 150 | 0.040 |
Why?
| | Chromosomes, Human, Pair 14 | 1 | 1997 | 17 | 0.040 |
Why?
| | Interleukin-1 | 1 | 2002 | 980 | 0.040 |
Why?
| | Oxidation-Reduction | 1 | 2020 | 940 | 0.040 |
Why?
| | Ganciclovir | 1 | 1996 | 46 | 0.040 |
Why?
| | Indoles | 1 | 2019 | 316 | 0.040 |
Why?
| | Socioeconomic Factors | 1 | 2001 | 1128 | 0.040 |
Why?
| | Chromosome Deletion | 1 | 1997 | 95 | 0.040 |
Why?
| | Health Facility Size | 1 | 2016 | 12 | 0.040 |
Why?
| | Hospitals, Private | 1 | 2016 | 12 | 0.040 |
Why?
| | Cell Differentiation | 2 | 2011 | 1752 | 0.040 |
Why?
| | Chorionic Gonadotropin | 1 | 2016 | 80 | 0.040 |
Why?
| | Mass Spectrometry | 1 | 2019 | 681 | 0.040 |
Why?
| | Ifosfamide | 1 | 1996 | 31 | 0.030 |
Why?
| | AC133 Antigen | 1 | 2015 | 20 | 0.030 |
Why?
| | Time Factors | 2 | 2019 | 6409 | 0.030 |
Why?
| | Cell Separation | 1 | 2017 | 296 | 0.030 |
Why?
| | RNA-Binding Proteins | 1 | 2019 | 371 | 0.030 |
Why?
| | Cell Line, Transformed | 1 | 1996 | 136 | 0.030 |
Why?
| | Tissue Array Analysis | 1 | 2015 | 52 | 0.030 |
Why?
| | Hospital Charges | 1 | 1996 | 42 | 0.030 |
Why?
| | Marriage | 1 | 2017 | 109 | 0.030 |
Why?
| | Hospitals, Teaching | 1 | 2016 | 104 | 0.030 |
Why?
| | Antigens, Neoplasm | 1 | 2017 | 227 | 0.030 |
Why?
| | Cystadenocarcinoma, Papillary | 1 | 1995 | 5 | 0.030 |
Why?
| | Caspase 3 | 1 | 2016 | 243 | 0.030 |
Why?
| | Tumor Burden | 1 | 2016 | 274 | 0.030 |
Why?
| | DNA Mismatch Repair | 1 | 2015 | 28 | 0.030 |
Why?
| | Carboplatin | 1 | 1996 | 142 | 0.030 |
Why?
| | Cell Cycle Proteins | 1 | 2019 | 565 | 0.030 |
Why?
| | Ataxia Telangiectasia Mutated Proteins | 1 | 2015 | 62 | 0.030 |
Why?
| | Ileus | 1 | 2015 | 10 | 0.030 |
Why?
| | Disease Management | 1 | 2019 | 569 | 0.030 |
Why?
| | Genes, p53 | 1 | 1995 | 64 | 0.030 |
Why?
| | Income | 1 | 2016 | 173 | 0.030 |
Why?
| | Urinary Retention | 1 | 2015 | 19 | 0.030 |
Why?
| | Elective Surgical Procedures | 1 | 2016 | 160 | 0.030 |
Why?
| | Female Urogenital Diseases | 1 | 2014 | 5 | 0.030 |
Why?
| | Taxoids | 1 | 2015 | 98 | 0.030 |
Why?
| | Morbidity | 1 | 2015 | 296 | 0.030 |
Why?
| | Receptors, Androgen | 1 | 2015 | 134 | 0.030 |
Why?
| | RNA Interference | 1 | 2016 | 460 | 0.030 |
Why?
| | Histones | 1 | 2019 | 552 | 0.030 |
Why?
| | Bevacizumab | 1 | 2015 | 124 | 0.030 |
Why?
| | Intraoperative Complications | 1 | 2015 | 131 | 0.030 |
Why?
| | Sensitivity and Specificity | 1 | 2019 | 1795 | 0.030 |
Why?
| | Reference Values | 1 | 1996 | 774 | 0.030 |
Why?
| | Blood Volume | 1 | 2014 | 58 | 0.030 |
Why?
| | Drug Administration Schedule | 1 | 2016 | 736 | 0.030 |
Why?
| | Multivariate Analysis | 2 | 1996 | 1473 | 0.030 |
Why?
| | Infusions, Parenteral | 1 | 2014 | 37 | 0.030 |
Why?
| | Point Mutation | 1 | 1995 | 228 | 0.030 |
Why?
| | Bleomycin | 1 | 1996 | 228 | 0.030 |
Why?
| | Polyethyleneimine | 1 | 2014 | 18 | 0.030 |
Why?
| | Pelvis | 1 | 2015 | 92 | 0.030 |
Why?
| | Deoxycytidine | 1 | 2015 | 136 | 0.030 |
Why?
| | Insurance, Health | 1 | 2016 | 244 | 0.030 |
Why?
| | Hemostatics | 1 | 2014 | 50 | 0.030 |
Why?
| | DNA, Viral | 1 | 1996 | 356 | 0.030 |
Why?
| | Drainage | 1 | 2014 | 157 | 0.030 |
Why?
| | Tumor Suppressor Proteins | 1 | 2016 | 289 | 0.030 |
Why?
| | Anemia | 1 | 2015 | 146 | 0.030 |
Why?
| | Receptors, Progesterone | 1 | 2015 | 325 | 0.030 |
Why?
| | Referral and Consultation | 1 | 2018 | 648 | 0.030 |
Why?
| | Urban Population | 1 | 2016 | 409 | 0.030 |
Why?
| | Lipids | 1 | 2017 | 607 | 0.030 |
Why?
| | Preoperative Care | 1 | 2015 | 332 | 0.030 |
Why?
| | Biomarkers | 1 | 2024 | 3588 | 0.030 |
Why?
| | Gene Transfer Techniques | 1 | 2014 | 154 | 0.030 |
Why?
| | Thrombocytopenia | 1 | 2015 | 185 | 0.030 |
Why?
| | Patient Readmission | 1 | 2018 | 634 | 0.030 |
Why?
| | Polymorphism, Single-Stranded Conformational | 3 | 1998 | 30 | 0.030 |
Why?
| | Membrane Proteins | 1 | 2019 | 1055 | 0.030 |
Why?
| | Rural Population | 1 | 2016 | 452 | 0.030 |
Why?
| | Cholesterol | 1 | 2014 | 373 | 0.030 |
Why?
| | Ultrasonography | 1 | 2016 | 716 | 0.030 |
Why?
| | Linear Models | 1 | 1994 | 827 | 0.030 |
Why?
| | Zinc Finger E-box-Binding Homeobox 1 | 1 | 2011 | 25 | 0.030 |
Why?
| | Perioperative Period | 1 | 2011 | 50 | 0.030 |
Why?
| | Protein Kinase Inhibitors | 1 | 2017 | 811 | 0.030 |
Why?
| | Analysis of Variance | 1 | 1994 | 1293 | 0.030 |
Why?
| | Mutant Proteins | 1 | 2011 | 100 | 0.020 |
Why?
| | Risk Reduction Behavior | 1 | 2013 | 199 | 0.020 |
Why?
| | DNA Fragmentation | 1 | 2011 | 48 | 0.020 |
Why?
| | Comorbidity | 1 | 2016 | 1525 | 0.020 |
Why?
| | Fas Ligand Protein | 1 | 2011 | 60 | 0.020 |
Why?
| | Tomography, X-Ray Computed | 2 | 2014 | 2436 | 0.020 |
Why?
| | Hyperplasia | 1 | 2011 | 170 | 0.020 |
Why?
| | Neovascularization, Pathologic | 1 | 2012 | 287 | 0.020 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2015 | 667 | 0.020 |
Why?
| | Neoplasm Transplantation | 1 | 2011 | 245 | 0.020 |
Why?
| | Administration, Oral | 1 | 2012 | 756 | 0.020 |
Why?
| | Epithelial-Mesenchymal Transition | 1 | 2011 | 176 | 0.020 |
Why?
| | Pregnancy Complications | 1 | 2014 | 448 | 0.020 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2017 | 2061 | 0.020 |
Why?
| | Quality of Life | 1 | 2020 | 2363 | 0.020 |
Why?
| | Polyethylene Glycols | 1 | 2014 | 578 | 0.020 |
Why?
| | Regression Analysis | 1 | 2011 | 983 | 0.020 |
Why?
| | Receptors, Urokinase Plasminogen Activator | 1 | 2008 | 14 | 0.020 |
Why?
| | Patient Discharge | 1 | 2015 | 796 | 0.020 |
Why?
| | Injections, Subcutaneous | 1 | 2008 | 138 | 0.020 |
Why?
| | Placebos | 1 | 2008 | 202 | 0.020 |
Why?
| | Sulfonamides | 1 | 2011 | 445 | 0.020 |
Why?
| | Mice, Hairless | 1 | 2008 | 59 | 0.020 |
Why?
| | Blotting, Western | 1 | 2011 | 1194 | 0.020 |
Why?
| | Quality Improvement | 1 | 2015 | 963 | 0.020 |
Why?
| | Enzyme Inhibitors | 1 | 2011 | 827 | 0.020 |
Why?
| | Disease Models, Animal | 1 | 2016 | 3730 | 0.020 |
Why?
| | Chromosome Mapping | 2 | 1998 | 509 | 0.020 |
Why?
| | Molecular Sequence Data | 3 | 1996 | 2869 | 0.020 |
Why?
| | Genetic Markers | 2 | 1998 | 348 | 0.020 |
Why?
| | Receptors, Cell Surface | 1 | 2008 | 367 | 0.020 |
Why?
| | Cross-Sectional Studies | 1 | 2017 | 4551 | 0.020 |
Why?
| | Frameshift Mutation | 2 | 1996 | 28 | 0.020 |
Why?
| | Carcinosarcoma | 1 | 2005 | 17 | 0.020 |
Why?
| | Gene Deletion | 2 | 1998 | 361 | 0.020 |
Why?
| | Cohort Studies | 1 | 2015 | 5116 | 0.020 |
Why?
| | Anti-Bacterial Agents | 1 | 2014 | 1510 | 0.020 |
Why?
| | DNA Mutational Analysis | 2 | 1996 | 381 | 0.020 |
Why?
| | Colorado | 1 | 2014 | 4193 | 0.020 |
Why?
| | Severity of Illness Index | 1 | 2011 | 2673 | 0.010 |
Why?
| | Male | 2 | 2020 | 57784 | 0.010 |
Why?
| | Obesity | 1 | 2016 | 2746 | 0.010 |
Why?
| | Base Sequence | 2 | 1996 | 2158 | 0.010 |
Why?
| | Loss of Heterozygosity | 1 | 1998 | 40 | 0.010 |
Why?
| | Microsatellite Repeats | 1 | 1998 | 143 | 0.010 |
Why?
| | Actuarial Analysis | 1 | 1996 | 23 | 0.010 |
Why?
| | Genes, Neoplasm | 1 | 1995 | 21 | 0.010 |
Why?
| | BRCA1 Protein | 1 | 1995 | 57 | 0.010 |
Why?
| | Age of Onset | 1 | 1996 | 467 | 0.010 |
Why?
| | Sequence Analysis, DNA | 1 | 1998 | 755 | 0.010 |
Why?
| | Introns | 1 | 1995 | 234 | 0.010 |
Why?
| | Exons | 1 | 1995 | 307 | 0.010 |
Why?
| | Amino Acid Sequence | 1 | 1995 | 2070 | 0.010 |
Why?
|
|
Behbakht's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|